Publication | Closed Access

A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma

OncologyPhase Ii TrialMedicineMetastatic Colorectal CarcinomaPathologyColorectal CancerCancer TreatmentPharmacologyRadiation Oncology